Adverse effects of anticholinergic medication on positive schizophrenic symptoms

Psychological Medicine
E C JohnstoneS J Gamble

Abstract

In a series of 36 patients with acute schizophrenia flupenthixol dosage was blindly adjusted to give a fixed level of sedation. Patients were than randomly allocated to procyclidine or placebo. The patients receiving procyclidine experienced more positive schizophrenic symptoms and less severe extrapyramidal features by comparison with placebo patients. Blood levels of prolactin and flupenthixol estimated by radioimmunoassay were not significantly changed by the addition of procyclidine. Flupenthixol dosage and levels and prolactin levels were significantly related. There was no significant association between clinical and laboratory measures, with the exception that a curvilinear (inverted U) relationship was demonstrated between flupenthixol levels and antipsychotic and extrapyramidal effects. This relationship may be due to the fact that, in a study of this design, patients resistant to the effects of neuroleptic medication are likely to be given the highest doses. The findings support earlier claims that anticholinergic medication has adverse effects on schizophrenic symptoms.

References

Jan 1, 1978·Archives of General Psychiatry·P H GruenF S Halpern
Dec 1, 1977·American Journal of Surgery·R E CasaliB W Thompson
Sep 1, 1977·The British Journal of Psychiatry : the Journal of Mental Science·R G McCreadie, I M MacDonald
Mar 1, 1978·Psychopharmacology·D F KripkeJ Hernandez
Jan 1, 1979·Journal of the American Academy of Child Psychiatry·J F McDermott
Jan 1, 1979·Neuropsychobiology·S LalJ L DeRivera
Oct 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·T KolakowskaM Franklin
Dec 2, 1977·European Journal of Clinical Pharmacology·B Beermann, M Groschinsky-Grind
Apr 1, 1977·Acta Psychiatrica Scandinavica·M KrawieckaM Vaughan
Jul 1, 1977·The American Journal of Psychiatry·K Macvicar
Apr 1, 1975·The Journal of Nervous and Mental Disease·M M Singh, S R Kay
Mar 1, 1976·Archives of General Psychiatry·H Y Meltzer, V S Fang
Jul 26, 1969·Lancet·R B Godwin-AustenH W Kok
Feb 7, 1970·Lancet·J D ParkesR P Knill-Jones
Jun 1, 1974·The Journal of Obstetrics and Gynaecology of the British Commonwealth·P A NivenW N Spellacy
Jan 1, 1974·Archives of General Psychiatry·T Van PuttenM D Malkin
Oct 1, 1973·The American Journal of Psychiatry·F SangiovanniP Gaztanaga
Dec 1, 1973·The American Journal of Psychiatry·D S JanowskyH J Sekerke
Mar 1, 1974·The American Journal of Psychiatry·P T Donlon, J P Tupin
Apr 3, 1972·JAMA : the Journal of the American Medical Association·M K el-YosefH J Sekerke
Oct 1, 1972·Psychological Reports·W F Gross, V J Nerviano
Jun 1, 1967·The American Journal of Psychiatry·C P Chien, A Dimascio
Apr 1, 1970·Archives of General Psychiatry·S H CurryD S Janowsky
Feb 1, 1967·The British Journal of Psychiatry : the Journal of Mental Science·D A Stephens
Jan 1, 1980·Psychopharmacology·U HalbreichF S Halpern

❮ Previous
Next ❯

Citations

Jun 1, 1988·Biological Psychiatry·S P MahadikS E Karpiak
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank P BymasterDavid L Mckinzie
Feb 27, 2004·Schizophrenia Research·Ric M ProcyshynDeborah L Thompson
Aug 21, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Ann M Mortimer
Jan 1, 1993·Psychopharmacology·W YisakS Ogenstad
Apr 1, 1988·Social Psychiatry and Psychiatric Epidemiology·S Compton, T Brugha
Jan 1, 1991·The International Journal of Neuroscience·R Sandyk, S R Kay
Nov 1, 1990·The International Journal of Neuroscience·R Sandyk, S R Kay
Mar 16, 2007·Acta Psychiatrica Scandinavica·J EberhardS Levander
Oct 10, 2013·Psychiatry and Clinical Neurosciences·Shin OginoNoboru Yamaguchi
Aug 25, 2006·Schizophrenia Research·Marci L ChewGeorges Gharabawi
Apr 29, 1998·The Psychiatric Clinics of North America·X F Amador, J M Gorman
Sep 1, 1987·Biological Psychiatry·J Fritze, H Beckmann
Dec 18, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·François LaplanteRon M Sullivan
Jan 1, 1985·International Journal of Psychiatry in Medicine·S R Kay, L A Opler
Feb 1, 1996·The Australian and New Zealand Journal of Psychiatry·C Pantelis, T R Barnes
Jun 1, 1989·The Australian and New Zealand Journal of Psychiatry·R Miller
Jun 1, 1986·The Australian and New Zealand Journal of Psychiatry·G Caradoc-DaviesP E Mullen
Oct 2, 2003·The Annals of Pharmacotherapy·Stanford S JheeSteve J Sims
Jun 30, 2005·Journal of Psychiatric Practice·Leslie CitromeJan Volavka
Sep 15, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Segev Barak, Ina Weiner
Jan 1, 1996·Acta Psychiatrica Scandinavica. Supplementum·L C Kopala
May 1, 1991·Acta Psychiatrica Scandinavica·T WhiteJ P Woods
Sep 1, 1991·Acta Psychiatrica Scandinavica·S D Soni, M Brownlee
Dec 17, 2009·Psychopharmacology·Morgane ThomsenS Barak Caine
Dec 6, 2006·Molecular Psychiatry·T J RaedlerB Dean
Jun 4, 2008·Expert Opinion on Pharmacotherapy·Praveen Dayalu, Kelvin L Chou
Oct 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·D J KingR A Lucas
Jul 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·A RifkinR Munne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here